Business
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technologyORLANDO, FL / ACCESSWIRE / September 20, 2023 / Nutriband Inc.
About this update from Nutriband Inc.
[{"type":"text","content":"Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technologyORLANDO, FL / ACCESSWIRE / September 20, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 11,759,431 for Nutriband's proprietary AVERSA™ abuse deterrent technology utilizing taste aversion to address the primary routes of abuse of opioid based transdermal patches.The issuance of this patent, entitled, \"Abuse and Misuse Deterrent Transdermal Systems,\" further expands Nutriband's intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its proprietary AVERSA™ abuse deterrent technology. This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband's lead product under development is AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system, with the potential to become the first abuse deterrent pain patch on the market. AVERSA™ Fentanyl is estimated to have the potential to reach peak annual U.S. sales of $80M - $200M.1\"The issuance of this patent covering our AVERSA™abuse deterrent transdermal technology that utilizes taste aversion to address a primary route of abuse of opioid patches is an important component of our global IP portfolio.\" stated Gareth Sheridan, Nutriband CEO. \"This new patent strengthens our intellectual property position, which includes patents issued in 45 countries around the world.\"1 Health Advances market analysis report 2022About AVERSA™ TechnologyNutriband's AVERSA™ abuse deterrent transdermal technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.About ...